REGENXBIO Inc. (RGNX)
- Previous Close
16.11 - Open
16.01 - Bid 15.58 x 100
- Ask 15.72 x 200
- Day's Range
15.32 - 16.26 - 52 Week Range
11.83 - 28.80 - Volume
574,896 - Avg. Volume
743,745 - Market Cap (intraday)
769.48M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-6.02 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.83
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
www.regenxbio.comRecent News: RGNX
Performance Overview: RGNX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGNX
Valuation Measures
Market Cap
790.08M
Enterprise Value
604.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.81
Price/Book (mrq)
2.53
Enterprise Value/Revenue
6.69
Enterprise Value/EBITDA
-2.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-291.99%
Return on Assets (ttm)
-23.49%
Return on Equity (ttm)
-63.65%
Revenue (ttm)
90.24M
Net Income Avi to Common (ttm)
-263.49M
Diluted EPS (ttm)
-6.02
Balance Sheet and Cash Flow
Total Cash (mrq)
275.26M
Total Debt/Equity (mrq)
58.81%
Levered Free Cash Flow (ttm)
-133.51M
Research Analysis: RGNX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: RGNX
RGNX: Lowering target price to $18.00
REGENXBIO INC has an Investment Rating of HOLD; a target price of $18.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetRGNX: Lowering target price to $20.00
REGENXBIO INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetRGNX: Raising target price to $21.00
REGENXBIO INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetRGNX: Rating increased to a HOLD
REGENXBIO INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice Target